Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

To Compare effects of Fingolimod and Natalizumab on preventing regional grray matter and white matter atrophy in patients with relapsing-remitting Multiple Sclerosis

Trial Profile

To Compare effects of Fingolimod and Natalizumab on preventing regional grray matter and white matter atrophy in patients with relapsing-remitting Multiple Sclerosis

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Oct 2018

At a glance

  • Drugs Natalizumab (Primary) ; Fingolimod
  • Indications Multiple sclerosis
  • Focus Therapeutic Use
  • Most Recent Events

    • 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis
    • 29 Jul 2018 New trial record
    • 19 Jun 2018 Results presented at the 4th Congress of the European Academy of Neurology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top